Abstract

Background: Tuberculosis (TB) preventive therapy is crucial in combating the global TB epidemic. However, adverse drug reactions (ADRs) remain a significant barrier to its successful implementation. Methods: This prospective observational study involved 152 participants on TB preventive therapy, monitored over nine months to identify the incidence, type, and severity of ADRs, and assess the impact on treatment adherence. Results: A high incidence of ADRs was observed, with 88.2% of participants experiencing at least one ADR. Gastrointestinal side effects were the most common (41.4%), followed by hepatotoxicity (21.7%). The study also found an increased risk of ADRs among older adults (P=0.033), individuals with a higher BMI (P=0.015), and patients with diabetes mellitus (P=0.042). Despite this, high rates of treatment adherence and completion (92.1%) were achieved, indicating effective management of ADRs. Conclusion: The study highlights the prevalence of ADRs in TB preventive therapy but also demonstrates the effectiveness of current management strategies. Tailored monitoring and management strategies for high-risk groups are essential to enhance treatment safety and efficacy.

Description